Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 21 (6), 1097-102

The Value of Quantitative Measurement of HBeAg and HBsAg Before Interferon-Alpha Treatment of Chronic Hepatitis B in Children

Affiliations
Clinical Trial

The Value of Quantitative Measurement of HBeAg and HBsAg Before Interferon-Alpha Treatment of Chronic Hepatitis B in Children

B Burczynska et al. J Hepatol.

Abstract

Serum concentrations of HBsAg, HBeAg and hepatitis B virus DNA were measured quantitatively before interferon treatment in 23 children (17 boys, 6 girls) suffering from chronic hepatitis B, and correlated to the outcome of the treatment. Five children remained HBsAg- and HBeAg-positive throughout the treatment and 6 months after the end of the treatment (non-responders), 12 children eliminated HBeAg but not HBsAg (partial responders) and six eliminated HBeAg and HBsAg (complete responders). The five non-responders had significantly higher initial HBsAg and HBeAg concentrations and significantly lower alanine aminotransferase levels than the partial or complete responders. The six complete responders had significantly lower HBsAg concentrations than the partial or non-responders, and seemed to be younger. No significant difference in HBV DNA levels was found in the three response groups. These data suggest that quantitative assays of HBsAg and HBeAg are particularly useful in selecting patients with chronic hepatitis B for interferon therapy.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

Publication types

LinkOut - more resources

Feedback